CoviTact
Start date:14/12/2020 Main trial site:
Royal Infirmary of Edinburgh
The CoviTact trial aims to collect saliva samples from COVID positive and negative patients in order to evaluate a new assay developed to detect the presence of SARS-COVID 2.
Samples are collected as part of ongoing studies and will be tested using the novel assay and via PCR.
Research Team
Julia Grahamslaw
Lead Research Nurse
More EMERGE Trials
People who develop an Acute Kidney Injury (AKI) often have a poor prognosis and many go on to develop chronic kidney disease (CKD). The recognition that AKI and CKD are linked is recent and the molecular pathways that control the transition from acute injury to chronic disease are not well defined. Currently there are no specific treatments that reduce the risk of progressing to CKD after AKI.
Preliminary investigations (not yet published) suggest that AKI causes sustained activation of the endothelin (ET) system to the long-term detriment of renal and systemic haemodynamic function. These pilot data form the basis of our project that seeks to determine whether the ET system is active in patients with AKI and, thus, represents a potential target for therapeutic intervention.
KRAKIL aims to recruit altogether 100 patients from across the emergency department, acute medical unit and inpatient wards at the Royal Infirmary. 50 of which with AKI’s and 50 matched controls with normal kidney function. We will monitor their bloods and urine for 90 days and compare the data from between the two groups.